Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia

Bibliography

• American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
   PubMed Web of Science ®Google Scholar
• Heyland DK, Cook DJ, Griffith L, The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Canadian Critical Trials Group. Am J Respir Crit Care Med 1999;159:1249-56
   PubMed Web of Science ®Google Scholar
• Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33:2184-93
   PubMed Web of Science ®Google Scholar
• Kollef MH, Shorr A, Tabak YP, Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-62
   PubMed Web of Science ®Google Scholar
• Klevens RM, Edwards JR, Tenover FC, Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006;42:389-91
   PubMed Web of Science ®Google Scholar
• Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412-20
   PubMed Web of Science ®Google Scholar
• Luna CM, Vujacich P, Niederman MS, Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676-85
   PubMed Web of Science ®Google Scholar
• Rotstein C, Evans G, Born A, Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol 2008;19:19-53
   PubMed Web of Science ®Google Scholar
• Torres A, Ewig S, Lode H, Carlet J. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 2009;35:9-29
   PubMed Web of Science ®Google Scholar
• Corey GR, Stryjewski ME, Weyenberg W, Telavancin. Nat Rev Drug Discov 2009;8:929-30
   Google Scholar
• Levine DP. Vancomycin: a history. Clin Infect Dis 2006;42(Suppl 1):S5-12
   PubMed Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42(Suppl 1):S35-9
   PubMedGoogle Scholar
• Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007;60:788-94
   PubMed Web of Science ®Google Scholar
• Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44:3883-6
   PubMed Web of Science ®Google Scholar
• Sader HS, Fey PD, Limaye AP, Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009;53:4127-32
   PubMed Web of Science ®Google Scholar
• Hidayat LK, Hsu DI, Quist R, High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44
   PubMed Web of Science ®Google Scholar
• Lodise TP, Graves J, Evans A, Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-20
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA, Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200
   PubMed Web of Science ®Google Scholar
• Chang FY, Peacock JE Jr, Musher DM, Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003;82:333-9
   PubMed Web of Science ®Google Scholar
• Gonzalez C, Rubio M, Romero-Vivas J, Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-7
   PubMed Web of Science ®Google Scholar
• Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:3731-3
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Szczech LA, Benjamin DK Jr, Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44:190-6
   PubMed Web of Science ®Google Scholar
• Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003;51:1261-8
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Lomaestro BM, Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14
   PubMed Web of Science ®Google Scholar
• Cruciani M, Gatti G, Lazzarini L, Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-9
   PubMed Web of Science ®Google Scholar
• Georges H, Leroy O, Alfandari S, Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997;16:385-8
   PubMed Web of Science ®Google Scholar
• Lamer C, de Beco V, Soler P, Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281-6
   PubMed Web of Science ®Google Scholar
• ZYVOX®; (linezolid) injection; (linezolid) tablets; (linezolid) for oral suspension [Package insert]. Pfizer, Inc., 2010
   Google Scholar
• Boselli E, Breilh D, Rimmele T, Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005;33:1529-33
   PubMed Web of Science ®Google Scholar
• Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-80
   PubMed Web of Science ®Google Scholar
• Honeybourne D, Tobin C, Jevons G, Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003;51:1431-4
   PubMed Web of Science ®Google Scholar
• Kalil AC, Murthy MH, Hermsen ED, Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010;38:1802-8
   PubMed Web of Science ®Google Scholar
• Powers JH, Ross DB, Lin D, Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumoniae: the subtleties of subgroup analyses. Chest 2004;126:314-15
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Rello J, Cammarata SK, Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumoniae. Chest 2003;124:1789-97
   PubMed Web of Science ®Google Scholar
• Kunkel M, Chastre JE, Kollef M, Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus. Presented at the Infectious Diseases Society of America 48th Annual Meeting October 21-24, 2010; Vancouver, Canada
   Google Scholar
• Cubicin® (daptomycin for injection) [Package insert]. Cubist Pharmaceuticals, Inc., 2010
   Google Scholar
• TYGACIL® (tigecycline) FOR INJECTION for intravenous use [Package insert]. Wyeth Pharmaceuticals, Inc., 2010
   Google Scholar
• Pertel PE, Bernardo P, Fogarty C, Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008;46:1142-51
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, Vanpraagh AD, Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52
   PubMed Web of Science ®Google Scholar
• Freire AT, Melnyk V, Kim MJ, Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51
   PubMed Web of Science ®Google Scholar
• File TM Jr, Low DE, Eckburg PB, Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase III trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010;51:1395-405
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH, Integrated analysis of CANVAS 1 and 2: phase III, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;51:641-50
   PubMed Web of Science ®Google Scholar
• Leadbetter MR, Adams SM, Bazzini B, Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) 2004;57:326-36
   PubMed Web of Science ®Google Scholar
• Gradelski E, Valera L, Kolek B, Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams. Int J Antimicrob Agents 2001;18:43-8
   Google Scholar
• Higgins DL, Chang R, Debabov DV, Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:1127-34
   PubMed Web of Science ®Google Scholar
• Lunde CS, Hartouni SR, Janc JW, Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009;53:3375-83
   PubMed Web of Science ®Google Scholar
• Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 2005;56:337-43
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 2004;48:2149-52
   PubMed Web of Science ®Google Scholar
• King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004;53:797-803
   PubMed Web of Science ®Google Scholar
• Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:338-43
   PubMed Web of Science ®Google Scholar
• Odenholt I, Lowdin E, Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother 2007;51:3311-16
   PubMed Web of Science ®Google Scholar
• Pace JL, Krause K, Johnston D, In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:3602-4
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2007;60:406-9
   PubMed Web of Science ®Google Scholar
• Hegde SS, Reyes N, Wiens T, Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob Agents Chemother 2004;48:3043-50
   PubMed Web of Science ®Google Scholar
• Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:3163-5
   PubMed Web of Science ®Google Scholar
• Reyes N, Skinner R, Benton BM, Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:462-5
   PubMed Web of Science ®Google Scholar
• Reyes N, Skinner R, Kaniga K, Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:4344-6
   PubMed Web of Science ®Google Scholar
• Stucki A, Gerber P, Acosta F, Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 2006;50:770-3
   PubMed Web of Science ®Google Scholar
• Shaw JP, Seroogy J, Kaniga K, Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49:195-201
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Leonard SN, Rhomberg PR, Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagn Microbiol Infect Dis 2008;60:441-4
   Google Scholar
• Shaw JP, Cheong J, Goldberg MR, Kitt MM. Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers. Antimicrob Agents Chemother 2010;54:3365-71
   PubMed Web of Science ®Google Scholar
• VIBATIV (telavancin) for injection. Astellas Pharma, Inc., 2009
   Google Scholar
• Goldberg MR, Wong SL, Shaw JP, Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy 2010;30:806-11
   PubMed Web of Science ®Google Scholar
• Goldberg MR, Wong SL, Shaw JP, Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy 2010;30:35-42
   PubMedGoogle Scholar
• Wong SL, Goldberg MR, Ballow CH, Effect of telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy 2010;30:136-43
   PubMedGoogle Scholar
• Sun HK, Duchin K, Nightingale CH, Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006;50:788-90
   PubMed Web of Science ®Google Scholar
• Barcia-Macay M, Mouaden F, Mingeot-Leclercq MP, Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J Antimicrob Chemother 2008;61:1288-94
   PubMed Web of Science ®Google Scholar
• Nguyen HA, Denis O, Vergison A, Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrob Agents Chemother 2009;53:1434-42
   PubMed Web of Science ®Google Scholar
• Gotfried MH, Shaw JP, Benton BM, Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother 2008;52:92-7
   PubMed Web of Science ®Google Scholar
• Lodise TP Jr, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2008;52:2300-4
   PubMed Web of Science ®Google Scholar
• Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008;52:24-36
   PubMed Web of Science ®Google Scholar
• Draghi DC, Benton BM, Krause KM, In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 2008;62:116-21
   PubMed Web of Science ®Google Scholar
• Draghi DC, Benton BM, Krause KM, Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52:2383-8
   PubMed Web of Science ®Google Scholar
• Hatano K, Matsuzaki K, Sato Y, In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006). J Antibiot (Tokyo) 2007;60:709-12
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Jones RN. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007 – 2008). Int J Antimicrob Agents 2010;36:374-9
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Mendes RE, Sader HS, Jones RN. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother 2010;65:2396-404
   PubMed Web of Science ®Google Scholar
• Putnam SD, Sader HS, Moet GJ, Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagn Microbiol Infect Dis 2010;67:359-68
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Chu VH, O'Riordan WD, Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-7
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, O'Riordan WD, Lau WK, Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin Infect Dis 2005;40:1601-7
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 2008;46:1683-93
   PubMed Web of Science ®Google Scholar
• Nannini EC, Stryjewski ME. A new lipoglycopeptide: telavancin. Expert Opin Pharmacother 2008;9:2197-207
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR, Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 2011;52:31-40
   PubMed Web of Science ®Google Scholar
• Barriere S, Genter F, Spencer E, Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004;44:689-95
   PubMed Web of Science ®Google Scholar
• Sivagnanam S, Deleu D. Red man syndrome. Crit Care 2003;7:119-20
   PubMed Web of Science ®Google Scholar
• NDA 22-110 VIBATIV™ (telavancin) risk evaluation and mitigation strategy (REMS). 2009
   Google Scholar
• Liu C, Bayer A, Cosgrove SE, Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55
   PubMed Web of Science ®Google Scholar
• Andrews J, Honeybourne D, Ashby J, Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J Antimicrob Chemother 2007;60:677-80
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Nicolau DP, Lodise TP, Identifying exposure targets for treatment of staphylococcal pneumoniae with ceftobiprole. Antimicrob Agents Chemother 2009;53:3294-301
   PubMed Web of Science ®Google Scholar
• Mimoz O, Rolland D, Adoun M, Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med 2006;32:775-9
   PubMed Web of Science ®Google Scholar
• Leonard SN, Rybak MJ. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious Gram-positive infections. Pharmacotherapy 2008;28:458-68
   PubMed Web of Science ®Google Scholar